Suppr超能文献

用于结构测定的原位蛋白酶解以生成晶体:最新进展。

In situ proteolysis to generate crystals for structure determination: an update.

作者信息

Wernimont Amy, Edwards Aled

机构信息

Midwest Center for Structural Genomics and Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.

出版信息

PLoS One. 2009;4(4):e5094. doi: 10.1371/journal.pone.0005094. Epub 2009 Apr 7.

Abstract

For every 100 purified proteins that enter crystallization trials, an average of 30 form crystals, and among these only 13-15 crystallize in a form that enables structure determination. In 2007, Dong et al reported that the addition of trace amounts of protease to crystallization trials--in situ proteolysis--significantly increased the number of proteins in a given set that produce diffraction quality crystals. 69 proteins that had previously resisted structure determination were subjected to crystallization with in situ proteolysis and ten crystallized in a form that led to structure determination (14.5% success rate). Here we apply in situ proteolysis to over 270 new soluble proteins that had failed in the past to produce crystals suitable for structure determination. These proteins had produced no crystals, crystals that diffracted poorly, or produced twinned and/or unmanageable diffraction data. The new set includes yeast and prokaryotic proteins, enzymes essential to protozoan parasites, and human proteins such as GTPases, chromatin remodeling proteins, and tyrosine kinases. 34 proteins yielded deposited crystal structures of 2.8 A resolution or better, for an overall 12.6% success rate, and at least ten more yielded well-diffracting crystals presently in refinement. The success rate among proteins that had previously crystallized was double that of those that had never before yielded crystals. The overall success rate is similar to that observed in the smaller study, and appears to be higher than any other method reported to rescue stalled protein crystallography projects.

摘要

每100种进入结晶试验的纯化蛋白质中,平均有30种能形成晶体,而在这些晶体中,只有13 - 15种的结晶形式能够用于结构测定。2007年,董等人报告称,在结晶试验中添加痕量蛋白酶——原位蛋白酶解——能显著增加给定蛋白质组中产生具有衍射质量晶体的蛋白质数量。69种先前无法进行结构测定的蛋白质进行了原位蛋白酶解结晶试验,其中10种结晶的形式可用于结构测定(成功率为14.5%)。在此,我们将原位蛋白酶解应用于270多种过去未能产生适合结构测定晶体的新可溶性蛋白质。这些蛋白质要么根本没有产生晶体,要么产生的晶体衍射效果差,要么产生孪晶和/或难以处理的衍射数据。新的蛋白质组包括酵母和原核生物蛋白质、原生动物寄生虫必需的酶以及人类蛋白质,如GTP酶、染色质重塑蛋白和酪氨酸激酶。34种蛋白质产生了分辨率为2.8埃或更高的已存入数据库的晶体结构,总体成功率为12.6%,目前至少还有10种产生了衍射良好的晶体,正在进行结构精修。先前已结晶的蛋白质的成功率是从未产生过晶体的蛋白质的两倍。总体成功率与规模较小的研究中观察到的相似,似乎高于报道的任何其他拯救停滞的蛋白质晶体学项目的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1819/2661377/9a336c165271/pone.0005094.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验